Author: admin

The neuroprotection biotech also strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist, to the Scientific Advisory Board. The ongoing phase 1 clinical trial of its neuroprotective and remyelinating compound BN201 is due for completion early 2019....

Bionure is expanding its Scientific Advisory Board with the appointment of Dr. Amit Bar-Or, Director of the Center for Neuroinflammation and Experimental Therapeutics and Chief of the Multiple Sclerosis Center at the University of Pennsylvania Perelman School of Medicine (Philadelphia, USA)....